MSD Korea to launch Vytorin for an anti-cholestrolemia.

Published: 2005-07-04 07:00:00

Updated: 2005-07-04 07:00:00

MSD Korea announced to launch Vytorin, a new type of anti-cholesterol drug containing 2 medicines, ezetimibe and simvastatin, blocking cholesterol absorption in duplicate in the process of cholesterol synthesis in the liver, starting from July 1 this year.

MSD Korea said that Vitorin is admini...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK